The history of the HIV/AIDS epidemic is marked by devastating losses and a disease burden that persists to this day. Though slow to emerge, both government policy and pharmaceutical research began to address the epidemic, and the resulting combinations of antiretroviral cocktails and outreach programs have helped make HIV infection a manageable, if inconvenient, chronic condition. In 2012, however, the FDA approved a drug that had the potential to shift both the American and global strategies regarding HIV and AIDS.
Though they make up 5.6 percent of the US population, discussions about Asian-American health appear to be few and far between. According to the Asian-American Health Initiative, a variety of medical and public health scourges disproportionately affect the Asian-American community. Some of these disparities entail disease incidence, while others describe a paucity of certain preventive health measures being delivered to this group.